In particular, immune checkpoint blockades that target to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) have succeeded clinically in human melanoma patients and were approved by the FDA in 2011 and 2014, respectively5. This evidence concerns the gene PDCD1 and melanoma.